MedTrace Logo

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

NCT02231658 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2018-10-17

No results posted yet for this study

Summary

The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.

Conditions

Interventions

DRUG

Liraglutide

DRUG

Lixisenatide

Sponsors & Collaborators

  • Profil Institut für Stoffwechselforschung GmbH

    lead INDUSTRY

Principal Investigators

  • Juris Meier, MD · St. Josef Hospital Bochum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-16
Primary Completion
2018-07-23
Completion
2018-07-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02231658 on ClinicalTrials.gov